Patents by Inventor Wan-Heng Wang

Wan-Heng Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170073681
    Abstract: RNA interference is provided for inhibition of Frizzled Related Protein-1 mRNA expression, in particular, for treating patients having glaucoma or at risk of developing glaucoma.
    Type: Application
    Filed: November 30, 2016
    Publication date: March 16, 2017
    Inventors: Abbot F. Clark, Wan-Heng Wang, Loretta Graves McNatt, Jon E. Chatterton
  • Patent number: 9550994
    Abstract: RNA interference is provided for inhibition of Frizzled Related Protein-1 mRNA expression, in particular, for treating patients having glaucoma or at risk of developing glaucoma.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: January 24, 2017
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Abbot F. Clark, Wan-Heng Wang, Loretta Graves McNatt, Jon E Chatterton
  • Publication number: 20150307882
    Abstract: RNA interference is provided for inhibition of Frizzled Related Protein-1 mRNA expression, in particular, for treating patients having glaucoma or at risk of developing glaucoma.
    Type: Application
    Filed: April 21, 2015
    Publication date: October 29, 2015
    Inventors: Abbot F. Clark, Wan-Heng Wang, Loretta Graves McNatt
  • Publication number: 20150225720
    Abstract: RNA interference is provided for inhibition of serum amyloid A mRNA expression in glaucomas involving SAA expression.
    Type: Application
    Filed: February 5, 2015
    Publication date: August 13, 2015
    Inventors: Abbot F. Clark, Wan-Heng Wang, Loretta Graves McNatt
  • Patent number: 9040494
    Abstract: RNA interference is provided for inhibition of Frizzled Related Protein-1 mRNA expression, in particular, for treating patients having glaucoma or at risk of developing glaucoma.
    Type: Grant
    Filed: March 26, 2012
    Date of Patent: May 26, 2015
    Assignee: NOVARTIS AG
    Inventors: Abbot F. Clark, Wan-Heng Wang, Loretta Graves McNatt, Jon E. Chatterton
  • Publication number: 20140357692
    Abstract: RNA interference is provided for inhibition of serum amyloid A mRNA expression in glaucomas involving SAA expression.
    Type: Application
    Filed: February 13, 2014
    Publication date: December 4, 2014
    Applicant: NOVARTIS AG
    Inventors: Abbot F. Clark, Wan-Heng Wang, Loretta Graves McNatt
  • Publication number: 20120178795
    Abstract: RNA interference is provided for inhibition of Frizzled Related Protein-1 mRNA expression, in particular, for treating patients having glaucoma or at risk of developing glaucoma.
    Type: Application
    Filed: March 26, 2012
    Publication date: July 12, 2012
    Applicant: NOVARTIS AG
    Inventors: Abbot F. Clark, Wan-Heng Wang, Loretta Graves McNatt, Jon E. Chatterton
  • Publication number: 20120122961
    Abstract: RNA interference is provided for inhibition of serum amyloid A mRNA expression in glaucomas involving SAA expression.
    Type: Application
    Filed: January 31, 2012
    Publication date: May 17, 2012
    Applicant: NOVARTIS AG
    Inventors: Abbot F. Clark, Wan-Heng Wang, Loretta McNatt
  • Patent number: 8173617
    Abstract: RNA interference is provided for inhibition of Frizzled Related Protein-1 mRNA expression, in particular, for treating patients having glaucoma or at risk of developing glaucoma.
    Type: Grant
    Filed: April 12, 2011
    Date of Patent: May 8, 2012
    Assignee: Novartis AG
    Inventors: Abbot F. Clark, Wan-Heng Wang, Loretta Graves McNatt, Jon E. Chatterton
  • Publication number: 20120064532
    Abstract: The present invention provides compositions and methods for treating glaucoma, methods for diagnosing glaucoma, and methods for identifying agents which may be useful in the treatment of glaucoma. More specifically, the present invention describes the use of agents that modulate the expression of serum amyloid A.
    Type: Application
    Filed: September 7, 2011
    Publication date: March 15, 2012
    Applicant: NOVARTIS AG
    Inventors: Abbot F. CLARK, Wan-Heng WANG, Loretta Graves McNATT
  • Publication number: 20110190381
    Abstract: RNA interference is provided for inhibition of Frizzled Related Protein-1 mRNA expression, in particular, for treating patients having glaucoma or at risk of developing glaucoma.
    Type: Application
    Filed: April 12, 2011
    Publication date: August 4, 2011
    Applicant: ALCON INC.
    Inventors: Abbot F. Clark, Wan-Heng Wang, Loretta Graves McNatt, Jon E. Chatterton
  • Patent number: 7947660
    Abstract: RNA interference is provided for inhibition of Frizzled Related Protein-1 mRNA expression, in particular, for treating patients having glaucoma or at risk of developing glaucoma.
    Type: Grant
    Filed: March 10, 2006
    Date of Patent: May 24, 2011
    Assignee: Alcon, Inc.
    Inventors: Abbot F. Clark, Wan-Heng Wang, Loretta Graves McNatt, Jon E. Chatterton
  • Publication number: 20110054008
    Abstract: RNA interference is provided for inhibition of serum amyloid A mRNA expression in glaucomas involving SAA expression.
    Type: Application
    Filed: October 26, 2010
    Publication date: March 3, 2011
    Applicant: ALCON, INC.
    Inventors: Abbot F. Clark, Wan-Heng Wang, Loretta McNatt
  • Patent number: 7879006
    Abstract: The present invention is an ophthalmic injection aid having a positioning member and a needle assembly. The injection aid facilitates the creation of an anterior juxtascleral depot of an ophthalmic drug.
    Type: Grant
    Filed: January 22, 2009
    Date of Patent: February 1, 2011
    Assignee: Alcon Research, Ltd.
    Inventors: Wan-Heng Wang, Liezhi Liang
  • Patent number: 7807355
    Abstract: Methods and compositions for diagnosing and treating glaucoma are disclosed.
    Type: Grant
    Filed: January 6, 2006
    Date of Patent: October 5, 2010
    Assignees: Alcon, Inc., University of Iowa Research Foundation
    Inventors: Abbot F. Clark, John Fingert, Loretta McNatt, Edwin M. Stone, Wan-Heng Wang
  • Patent number: 7807363
    Abstract: The present invention concerns a method for diagnosing or monitoring elevated intraocular pressure or glaucoma in a patient comprising providing a biological sample from the patient and measuring the expression level of a superoxide dismutase-2 (SOD-2) gene in the biological sample. The present invention also concerns methods for treating glaucoma or elevated intraocular pressure in a patient comprising administering to a patient an effective amount of an agent that modulates SOD-2 expression or SOD-2 activity.
    Type: Grant
    Filed: February 28, 2007
    Date of Patent: October 5, 2010
    Assignee: Alcon Research, Ltd.
    Inventors: Wan-Heng Wang, Loretta Graves McNatt, Abbot F. Clark, Peter G. Klimko
  • Publication number: 20100152279
    Abstract: RNA interference is provided for inhibition of serum amyloid A mRNA expression in glaucomas involving SAA expression.
    Type: Application
    Filed: February 25, 2010
    Publication date: June 17, 2010
    Applicant: ALCON, INC.
    Inventors: Abbot F. Clark, Wan-Heng Wang, Loretta McNatt
  • Publication number: 20100113481
    Abstract: The present invention provides compositions and methods for treating glaucoma, methods for diagnosing glaucoma, and methods for identifying agents which may be useful in the treatment of glaucoma. More specifically, the present invention describes the use of agents that modulate the expression of serum amyloid A, wherein such agents are inhibitors of p38 MAPkinase.
    Type: Application
    Filed: December 15, 2009
    Publication date: May 6, 2010
    Applicant: ALCON RESEARCH, LTD.
    Inventor: Wan-Heng Wang
  • Publication number: 20100063052
    Abstract: The present invention provides compositions and methods for treating glaucoma, methods for diagnosing glaucoma, and methods for identifying agents which may be useful in the treatment of glaucoma. More specifically, the present invention describes the use of agents that modulate the expression of serum amyloid A.
    Type: Application
    Filed: November 13, 2009
    Publication date: March 11, 2010
    Applicant: ALCON, INC.
    Inventors: Abbot F. Clark, Wan-Heng Wang, Loretta Graves McNatt
  • Patent number: 7662389
    Abstract: The present invention provides compositions and methods for treating glaucoma, methods for diagnosing glaucoma, and methods for identifying agents which may be useful in the treatment of glaucoma. More specifically, the present invention describes the use of agents that modulate the expression of serum amyloid A.
    Type: Grant
    Filed: December 22, 2006
    Date of Patent: February 16, 2010
    Assignee: Alcon, Inc.
    Inventors: Abbot F. Clark, Wan-Heng Wang, Loretta Graves McNatt